Drugs / Purity
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05935826 Comparator | Jun 2024 → Aug 2026 overdue | fatty liver disease | University of Colorado, Denver | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Purity | “2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA” NCT05935826 ↗ |